Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Sanara MedTech's fair value target has shifted from $36 to $34, a $2 adjustment that resets expectations around what investors might be willing to pay for the shares. Analysts link this move to a more balanced view that weighs the long term growth story against practical execution risks laid out in recent commentary. As you read on, you will see how this updated target fits into the evolving Street narrative and what to watch next in the story.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Lake Street recently initiated coverage on Sanara MedTech with a bullish stance, which supports the idea that some analysts still see an attractive long term opportunity despite the revised fair value target of $34.
-
The positive initiation from Lake Street suggests confidence in Sanara MedTech's ability to build on its current wound care and MedTech positioning. Investors are watching how that thesis lines up against execution over the next phase of the company's development.
🐻 Bearish Takeaways
-
The adjustment of the fair value target from $36 to $34 reflects a more cautious view on execution risk. This signals that not all elements of the growth story are being priced as aggressively as before.
-
Some investors may see the lower fair value target as a reminder that scaling a MedTech platform can come with timing and operational questions. This could limit how much they are willing to pay for the shares at this stage.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
What's in the News
-
Sanara MedTech reaffirmed full year 2026 net revenue guidance of US$116 million to US$121 million, which the company frames as approximately 13% to 17% growth versus 2025 net revenue of US$103.1 million.
-
The company issued Q4 2025 net revenue guidance of US$27.2 million to US$27.7 million, described as approximately 3% to 5% growth versus US$26.3 million in Q4 2024 and approximately 11% to 13% growth when adjusting for US$1.8 million of BIASURGE sales in Q4 2024.
-
Full year 2025 net revenue is guided to US$102.7 million to US$103.2 million, which Sanara MedTech describes as approximately 19% growth versus US$86.7 million in 2024, or approximately 21% to 22% growth excluding US$1.8 million of BIASURGE sales in Q4 2024.
-
A peer reviewed study in the Journal of Medical Economics reported that CellerateRX Surgical Powder, used as an adjunct to standard care in high risk spinal surgery patients, was associated with an estimated US$3,852 cost saving, a 0.007 QALY gain per patient and a net monetary benefit of US$4,542, with a dominant cost effectiveness profile in more than 99% of modeled simulations.
How This Changes the Fair Value For Sanara MedTech
-
Fair value target adjusted from US$36 to US$34, a US$2 reduction aligned with the updated outlook.
-
Revenue growth forecast revised from 12.85% to 12.61%.
-
Net profit margin assumption moved from 24.52% to 6.62%.
-
Future P/E multiple updated from 11.47x to 44.40x.
-
Discount rate assumption changed from 8.33% to 8.37%.
Never Miss an Update: Follow The Narrative
Narratives connect a company's business story to expectations for future earnings, margins, and risks. They update as new guidance, studies, and management actions come through, so you can see how the story is evolving in real time.
Head over to the Simply Wall St Community and follow the Narrative on Sanara MedTech to stay up to date on:
-
How expanding distributor and hospital relationships, along with underpenetrated specialties beyond core ortho and spine, feed into the revenue story for Sanara MedTech's wound and surgical care products.
-
The role of flagship products like CellerateRx, BIASURGE, and pipeline assets such as OsStic in widening the addressable market across surgical and bone fusion use cases.
-
Key risks around THP digital health investment outcomes, reliance on a focused US based product portfolio, and competition from larger medical technology and digital health players.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SMTI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
